IO Biotech (IOBT) Stock Price, News & Analysis

Company Overview

IO Biotech ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of novel immuno-oncology therapies. The company’s proprietary platform focuses on activating and sustaining anti-tumor immune responses by targeting the PD-L1 immune checkpoint. IO Biotech’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine designed to induce durable T-cell responses against PD-L1–expressing tumors.

Since its founding in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies in patients with metastatic melanoma. The company’s pipeline also explores combination regimens that pair its vaccine technology with established checkpoint inhibitors to enhance therapeutic efficacy. Research and development activities are conducted in Denmark, with ongoing collaborations and trial sites across Europe and North America to support global patient access.

IO Biotech is led by an experienced management team with deep expertise in immunology, oncology drug development and regulatory affairs. The company’s strategic focus remains on translating its innate immune-priming technology into differentiated cancer treatments and expanding its clinical footprint through partnerships and investigator-initiated studies.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: $0.03 to $0.21
• 52-Week Range: $0.03 to $2.79
• Volume: N/A
• Average Volume: 7.09 million shs
• Market Capitalization: $3.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Reduce

IO Biotech Stock Analysis - MarketRank™

IO Biotech scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

IO Biotech has received a consensus rating of Reduce. The company's average rating score is 1.60, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

IO Biotech has a consensus price target of $3.50, representing about 7,191.7% upside from its current price of $0.05.

Amount of Analyst Coverage

IO Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IO Biotech are expected to grow in the coming year, from ($1.35) to ($1.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IO Biotech is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IO Biotech is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IO Biotech has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for IOBT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IO Biotech does not currently pay a dividend.

Dividend Growth

IO Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for IOBT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IO Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.30% of the stock of IO Biotech is held by insiders.

Percentage Held by Institutions

54.76% of the stock of IO Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/14/2025
• Today: 6/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IOBT
• CIK: 1865494
• Web: www.iobiotech.com
• Phone: 45-7070-2980
• Fax: N/A
• Employees: 30
• Year Founded: 2014

Price Target and Rating

• Average Price Target for IO Biotech: $3.50
• High Price Target: $4.00
• Low Price Target: $3.00
• Potential Upside/Downside: +7,191.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$95.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -517.22%
• Return on Assets: -200.69%

Debt

• Debt-to-Equity Ratio: 18.29
• Current Ratio: 2.01
• Quick Ratio: 2.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.71 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 71,949,000
• Free Float: 68,495,000
• Market Cap: $3.45 million
• Optionable: Not Optionable
• Beta: 0.88